Korsana Biosciences, Inc.
private/Cyclerion Therapeutics, Inc.privateCyclerion to Merge with Korsana in Stock-for-Stock Transaction
Deal value
—
stock
Per-share offer
—
Premium
—
Days to close
—
Term fee
—
No structured deal economics extracted yet. Re-run the scanner or fall back to the source filing below.
Announced
Apr 24, 2026
Preliminary Proxy
—
Definitive Proxy
—
Record date
—
Shareholder vote
—
Expected close
—
No regulatory or closing-conditions data extracted yet. The merger agreement Exhibit 10.1 contains this in the “Conditions to Closing” and “Regulatory Approvals” articles.
No closing-condition data extracted.
No competing-bidder, activist, or dissident-proxy signals in the database for this target.
Acquirer side· Cyclerion Therapeutics, Inc.
Legal
- · William J. Michener
- · Zachary Blume
“William J. Michener, Esq. Zachary Blume, Esq. Ropes & Gray LLP Prudential Tower 800 Boylston Street Boston, Massachusetts 02199 (617) 951-7000”
Target side· Korsana Biosciences, Inc.
Legal
- · Ryan A. Murr
- · Branden C. Berns
“Ryan A. Murr, Esq. Branden C. Berns, Esq. Gibson, Dunn & Crutcher LLP One Embarcadero Center, Suite 2600 San Francisco, California 94111 (415) 393-8373”
| Firm | Role | Side | Deals in DB | |
|---|---|---|---|---|
| Gibson, Dunn & Crutcher LLP | Legal | Target | 5 | View deals → |
| Ropes & Gray LLP | Legal | Acquirer | 1 | View deals → |
Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. entered into a Merger Agreement on April 1, 2026 (amended April 17, 2026) pursuant to which Korsana shareholders will receive Cyclerion common stock, preferred stock, warrants, and options in exchange for their Korsana securities based on an exchange ratio. The combined company will be renamed Korsana Biosciences, Inc. with Korsana operating as a wholly-owned subsidiary. The transaction requires approval from shareholders of both companies.